Pharmaceuticals

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held inVienna from 9...

2023-09-06 14:18 2866

MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study

GENEVA, Sept. 6, 2023 /PRNewswire/ -- The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where ...

2023-09-06 08:00 3084

MALAYSIA HEALTHCARE TRAVEL COUNCIL SELECTS MAYO CLINIC TO PROVIDE STRATEGIC COUNSEL TO FURTHER ADVANCE MEDICAL EXCELLENCE IN MALAYSIA

PUTRAJAYA, Malaysia, Sept. 5, 2023 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC), an agency established under the purview of Ministry of Health Malaysia, has officially announced the successful establishment of a Memorandum of Understanding (MoU) with US-basedMayo Clinic

2023-09-05 22:37 3308

YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference

GAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious di...

2023-09-05 20:30 2432

Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile

Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products and their significant disadvantages.  Compared with other commercially available hyaluronidase products, Tergase® showed no incidence of anti-drug antibodies (ADA).  The occurrence of ADA is known ...

2023-09-05 20:00 3465

I-Mab Announces Upcoming Participation at September Conferences

ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies an...

2023-09-05 20:00 2124

ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001

*  Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform *  ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data *  ACM is in partnering d...

2023-09-05 14:00 2680

GCCL to be the first in the industry sector to adopt Lab Information Management System (LIMS)

* The first clinical trial sample analysis provider to adopt LIMS * To provide enhanced quality of pharmacokinetic, pharmacodynamic, and immunogenicity data from bioanalytic testing YONGIN, South Korea, Sept. 4, 2023 /PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, annou...

2023-09-05 09:57 1943

Seegene Unveils 'Open Innovation Program Powered by Seegene' in Partnership with Springer Nature

* The program is a part of the Seegene OneSystemTM business aimed at creating a 'world free from all diseases' * Collaborating with clinical researchers worldwide, Seegene will share its technologies and enable researchers to develop syndromic qPCR assays SEOUL, South Korea, Sept. 4, 2023 /PR...

2023-09-04 21:00 3541

National University Health System Launches World's First Public Hospital's Healthy Longevity Clinic at Alexandra Hospital

SINGAPORE, Sept. 2, 2023 /PRNewswire/ -- The National University Health System (NUHS), NUS Yong Loo Lin School of Medicine andAlexandra Hospital (AH ) have achieved a milestone by unveiling the world's inaugural Healthy Longevity Clinic by public healthcare. Located atSing...

2023-09-02 13:00 4812

ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors

SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignan...

2023-09-02 00:00 4192

Adicon Holdings Limited (9860.HK): Continuous growth in Core Operations, Consistent Profitability Enhancement

HANGZHOU, China, Sept. 1, 2023 /PRNewswire/ -- Adicon Holdings Limited (the "Company" or "Adicon"), one of the largest independent clinical laboratory (ICL) service providers listed on the Stock Exchange ofHong Kong (SEHK), has released its interim results for the first half of 2023. As a leading...

2023-09-01 21:30 7012

CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023

BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative therapies for rare diseases...

2023-08-31 15:15 4894

Tycoon Group Announces 2023 Interim Results

The Group's Revenue Hits New Heights Net profit for 1H2023 increased more than 2.8 times YoY Benefited from the Full Resumption of Normal Travel Revenue Continues to Generate Profit in Future Results Highlights * Since the full resumption of normal travel between Hong Kong, Macau and Mainland C...

2023-08-31 13:28 5292

Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

* Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. * All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing cohort and the treated patients exhibited encouraging...

2023-08-31 11:30 6587

Sirnaomics Announces 2023 Interim Results

Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics Business Highlights Promising progress in clinical development * After an End of Phase-II meeting and with guidance from the U.S. FDA, the Group is advancing the l...

2023-08-31 10:40 5854

LOTTE BIOLOGICS Holds 'ESG Declaration Ceremony'

* Announces Human Rights and Environmental Management Charter Alongside Annual Implementation Strategies within its Mid-to-Long-term ESG Roadmap * Strengthens Eco-friendly Policies, Including Greenhouse Gas Reduction Plans from the Initial Factory Design Stage SEOUL, South Korea, Aug. 30, 20...

2023-08-31 09:00 2903

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

* Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN) FLORENCE, Italy and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagno...

2023-08-30 23:15 3531

European Society of Cardiology Congress: Traditional Chinese Medicine Qili Qiangxin significantly reduces the risk of cardiovascular death and re-hospitalization due to heart failure

AMSTERDAM, Aug. 30, 2023 /PRNewswire/ -- The latest study indicates that adding TCM Qili Qiangxin Capsules (developed and produced by Yiling Pharmaceutical) to the standard of care for heart failure can significantly reduce the risk of re-hospitalization due to worsening heart failure and cardio...

2023-08-30 20:11 3399

Igniting Innovation, Catalyzing Changes: Bio Farma x MIT Hacking Medicine Hackathon Celebrates Success

JAKARTA, Indonesia, Aug. 30, 2023 /PRNewswire/ -- Bio Farma , Indonesia's state-owned pharmaceutical company, has successfully concluded theBio Farma x MIT Hacking Medicine on August 24 to 27, 2023 in Bali. Over the course of four days, the Hackathon oversaw 200 chos...

2023-08-30 16:16 2939
1 ... 220221222223224225226 ... 351